Oncology Data Advisor

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD. Building on the foundation of biomarker-driven care, this module focuses on optimizing treatment strategies for patients with esophagogastric cancer. Dr. Janjigian reviews the latest evidence on targeted therapies, immunotherapies, and combination regimens, as well as practical considerations for sequencing and selecting therapies. Gain actionable insights to enhance collaborative care and deliver the most effective, individualized treatment plans for your patients. Listen now! Click here to claim credit for this activity: https://bit.ly/3HtOziO Click here to listen to Module 1 of this series: https://bit.ly/45u106o

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD. In module 1, Dr. Janjigian provides an in-depth overview of the latest biomarkers—such as HER2, PD-L1, MMR/MSI-H, CLDN18.2, and FGFR2—and their role in guiding treatment decisions for esophagogastric cancer. Learn about current biomarker testing methods, interpretation of results, and how to integrate biomarker data into clinical practice to personalize therapy and improve patient outcomes. Listen now! Click here to claim you CE credit for this activity: https://bit.ly/45u106o Click here to continue listening to Module 2 of this series: https://bit.ly/3HtOziO

Genetic testing and counseling are crucial components of precision medicine in cancer care, enabling clinicians to deliver the right care, to the right patient, at the right time. i3 Health’s educational activity, Pathways to Precision: Integrating Genetic Counseling and Testing Into Cancer Care, provides a comprehensive foundation for incorporating these tools into practice. In this follow-up interview to the activity, co-chairs Dr. Filipa Lynce, Director of the Inflammatory Breast Cancer at Harvard Medical School, and Catherine Skefos, Certified Genetic Counselor at MD Anderson Cancer Center, share advances that have occurred in the field since the activity was recorded, including clinical trial updates and novel insights for clinicians. Click here to complete the free CME/NCPD/CE activity: bit.ly/3HqXjpX

i3 Health recently launched an exciting new online educational activity, “What’s New with HER2: Charting New Paths in NSCLC Care.” This two-part series dives deep into the evolving role of HER2 in non–small cell lung cancer (NSCLC). In a special interview, Dr. Julia Kathleen Rotow—Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School—shares the latest breakthroughs in treating HER2-mutated NSCLC. She highlights why ongoing medical education is crucial in this fast-changing field and offers her insights on where HER2-targeted therapies are headed next. Stay tuned after the interview to listen to Module 1 of this accredited activity! Click below to complete the claim your CE credit: Module 2: https://bit.ly/405xEJO Click below to complete the Module 1 from this series, HER2 in NSCLC: Actionable Insights and Testing Recommendations Module 1: https://bit.ly/49NCaQu

i3 Health recently launched an exciting new online educational activity, “What’s New with HER2: Charting New Paths in NSCLC Care.” This two-part series dives deep into the evolving role of HER2 in non–small cell lung cancer (NSCLC). In a special interview, Dr. Julia Kathleen Rotow—Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School—shares the latest breakthroughs in treating HER2-mutated NSCLC. She highlights why ongoing medical education is crucial in this fast-changing field and offers her insights on where HER2-targeted therapies are headed next. Stay tuned after the interview to listen to Module 1 of this accredited activity! Click below to complete the claim your CE credit: Module 1: https://bit.ly/49NCaQu Click below to complete the next Module in this series, Current and Emerging Treatments for HER2-Mutated NSCLC Module 2: https://bit.ly/405xEJO

Hurry—listen to Module 3 and claim your CME credit by August 19! Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application. In this final module, Dr. Charles Vega, Clinical Professor of Family Medicine at the University of California, Irvine, explores the practical implementation of multicancer early detection (MCED) tests in clinical practice. Gain valuable insights into how these groundbreaking innovations could transform cancer screening and improve patient outcomes. Remember, you have only until August 19 to listen and claim your CME credit! Click here to claim your credit: bit.ly/4b9JU00 Click here to download the slide deck: bit.ly/40AkmoP

Time is running out—listen to Module 2 and claim your CME credit by August 19! Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application. In Module 2, Dr. Charles Vega takes you deeper into the cutting-edge world of multicancer early detection (MCED) tests. With nearly 2 million new cancer cases expected in 2024, early detection is more important than ever. Dr. Vega reviews the latest clinical trial data on MCED tests for gynecologic, gastrointestinal, and hematologic cancers, and explores how these advances could revolutionize cancer screening and improve patient outcomes. Don’t forget—you must listen and claim your CME credit by August 19! Click here to claim your credit: bit.ly/41rS14I Click here to download the slide deck: bit.ly/4fdXwti

Don’t miss your chance—listen to Module 1 and claim your CME credit by August 19! Join Dr. Charles Vega, a distinguished Clinical Professor of Family Medicine at the University of California, Irvine, as he explores the cutting-edge field of multicancer early detection (MCED). In this engaging session, Dr. Vega delves into the scientific foundations of blood-based cancer screening, examining both current limitations and the exciting promise of MCED technologies. Discover how these innovative tests use biomarkers to detect multiple cancers in a single, convenient screening—offering a breakthrough solution to challenges like low awareness and limited access to screening facilities. Remember, you have only until August 19 to listen and earn your CME credit! Click here to claim your credit: bit.ly/3X8apxa Click here to download the slide deck: bit.ly/4l0NTzc

oin i3 Health for a special live webinar, Increasing Detection and Improving Outcomes in Hereditary Transthyretin Amyloid Cardiomyopathy, being held on Wednesday, July 30 at 5:00 pm ET. In this exclusive event, Dr. Mathew Maurer, the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, will share his expertise and latest insights in the treatment of hereditary ATTR-CM. In this interview, Dr. Maurer shares a preview of the topics he is excited to highlight during the webinar, including signs and symptoms to aid in early diagnosis, advances in genetic testing and new diagnostic modalities, novel therapies that are improving outcomes, and the role of interdisciplinary collaboration. Don’t miss this opportunity to learn from one of the leading voices in hereditary ATTR-CM care. Register at the link below or scan the QR code in the video to secure your spot. We look forward to seeing you! Register Here: bit.ly/3UgV7nF

Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Waqas Haque, a Hematology/Oncology Fellow at the University of Chicago, recently shared his perspectives on i3 Health’s CME activity, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With MCED testing moving from research to real-world practice, Dr. Haque discussed the science, challenges, and future of these innovative tests, as well as the importance of staying up to date on emerging advances with continuing education. Click the links below for the full CME activity! Module 1: https://bit.ly/3X8apxa Module 2 : https://bit.ly/41rS14I Module 3: https://bit.ly/4b9JU00 And view the slide decks here: Module 1: https://bit.ly/4l0NTzc Module 2: https://bit.ly/4fdXwti Module 3: https://bit.ly/40AkmoP

As research in dedifferentiated liposarcoma (DDLPS) continues to advance, the importance of multidisciplinary collaboration and access to innovative therapies remains at the forefront of patient care. Recently, Dr. Richard Riedel of Duke Cancer Institute and Dr. Candace Haddox of Dana-Farber Cancer Institute co-chaired i3 Health’s DDLPS Task Force activity, which brought together a panel of experts to address the complexities of this rare and challenging sarcoma subtype. With new clinical trials underway and a growing understanding of the disease’s molecular landscape, Dr. Riedel and Dr. Haddox sat down to highlight promising research directions and insights in honor of Sarcoma Awareness Month in July. After listening to the interview, stay tuned to hear the full accredited podcast with Dr. Riedel and Dr. Haddox, and click the link below to claim free CME/AAPA credit. Click the links below for the Task Force activity! - Accredited CME/AAPA Podcast: i3health.com/course-information/podcast-ddlps - Position St

Join i3 Health for a special live webinar, Optimizing Neuroendocrine Tumor Outcomes: Closing the Gaps in Diagnosis and Care, being held on Thursday, July 17th at 12:00 pm Eastern and on Tuesday, August 5th at 3:00 pm Eastern. In this exclusive event, Dr. Aman Chauhan, Leader of the Neuroendocrine Tumor Program at the University of Miami, Sylvester Comprehensive Cancer Center, will share his expertise and latest insights in the treatment of NETs. In this interview, Dr. Chauhan shares a preview of the topics he is excited to highlight during the webinar, including the recent advances which are transforming patient care, the emerging field of theranostics, the evolving role of multidisciplinary care, and practical tips for effective team collaboration. Don’t miss this opportunity to learn from one of the leading voices in NETs care. Register at the link below or scan the QR code in the video to secure your spot. We look forward to seeing you! Register Here! July 17, 2025 @ 12:00 PM ET: https://us02web.zoom.

A Return on Humanity: How the American Cancer Society Uses AI to Improve Patient Care by i3 Health

Biliary tract cancer (BTC) presents a complex puzzle for the interprofessional healthcare team. With its diverse subtypes and unique molecular features, diagnosis and treatment require a personalized approach. Stay ahead of the curve with insights from leading experts, Dr. Anjana Pillai and Dr. Rachna Shroff, as they explore the latest genomic research, targeted therapies, and emerging treatment strategies in this dynamic podcast. Listen now to hear the Multidisciplinary Task Force perspective and strategies to optimize patient care in this rapidly evolving landscape. Click here to claim your credit for this podcast:

Read the full article for this interview here: https://oncdata.com/standard-model-biomedicine Artificial intelligence (AI) is rapidly transforming the landscape of oncology, offering new tools to improve patient care and accelerate research. In this episode of Exploring AI in Oncology, Dr. Waqas Haque sat down with Kevin Brown, Founder and CEO of Standard Model Biomedicine, to discuss the challenges and opportunities of implementing AI in cancer care.

Read the full article here: https://oncdata.com/reimagining-oncology-nursing-through-ai In this episode of the Exploring AI in Oncology series, Dr. Waqas Haque, Hematology/Oncology Fellow at the University of Chicago, spoke with Kathleen McGrow, Sangeeta Agarawal, and Marc Perkins-Carrillo about their presentation at the Oncology Nursing Society (ONS) Congress about the intersection of artificial intelligence (AI) and oncology nursing. Their conversation highlights the transformative potential of AI in nursing, the skills needed to navigate this evolving landscape, and the ethical considerations that must guide its implementation.

In this concluding module, Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, addresses the critical challenges of managing treatment-associated toxicities in the era of advanced melanoma therapies. Discover practical strategies for handling immune-related adverse events, implementing comprehensive supportive care, and optimizing patient education. This podcast is critical for oncology professionals seeking to balance therapeutic efficacy with quality of life for patients receiving cutting-edge immunotherapy and targeted treatments. Click here to go back and listen to module 1 of this podcast series: [link] Click here to claim your CME/NCPD credit: [link]

Join melanoma authority Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, as he navigates the latest breakthroughs in immunotherapy and targeted treatments transforming outcomes for patients with melanoma. Discover how predictive biomarkers, strategic combination therapies, and personalized treatment sequencing are revolutionizing care across neoadjuvant, adjuvant, and metastatic settings. This podcast is essential listening for oncology professionals seeking evidence-based approaches to combat this challenging disease affecting over 100,000 Americans annually. Click here to listen to module 2 of this podcast series: [link] Click here to claim your CME/NCPD credit: [link]

In this episode of the Exploring AI in Oncology podcast, Waqas Haque, MD, MPH, a Hematology/Oncology Fellow at the University of Chicago, speaks with Samir Shah, MD, MMM, FACR, the Chief Medical Officer at Qure.ai. Their discussion explores how Qure.ai’s innovative AI solutions are addressing critical gaps in lung cancer screening and improving early detection through advanced image analysis and clinical data integration.

In Module 2 of this podcast series, discover strategies for developing personalized management plans for patients with systemic mastocytosis (SM), a rare disease with a wide spectrum of symptoms. This episode highlights the latest advancements in treatment, including tyrosine kinase inhibitors (TKIs), supportive care interventions, and approaches to tailoring therapies based on disease subtype and symptom burden to improve patient outcomes and quality of life. Listen now! Click here to claim credit for this activity: bit.ly/43VoFNP